Age (p = 0.037), follow-up period (p = 0.003), AST change (p = 0.038), ALT change (p < 0.001), APRI change (p = 0.011), and the frequencies of weight loss (p < 0.001) and starting to exercise (p = 0.008) differed significantly between those who demonstrated NAFLD remission and those who remained NAFLD. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.